Founded in 2001, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
The Company's principal executive offices are located in Rockville, MD.
Synthetic Biologics, Inc. is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections.
In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.